Back to Search
Start Over
Angiotensin-(1-7) Treatment Early in Life Prevents Cardiac Hypertrophy in Adult Hypertensive Rats.
- Source :
-
Journal of cardiovascular pharmacology [J Cardiovasc Pharmacol] 2024 May 01; Vol. 83 (5), pp. 457-465. Date of Electronic Publication: 2024 May 01. - Publication Year :
- 2024
-
Abstract
- Abstract: Angiotensin (Ang)-(1-7) is a cardioprotective peptide of the renin-angiotensin system. Prepuberty has been considered as a later susceptible window of development, and stressful factors in this life phase can induce chronic diseases in adulthood. We aimed to investigate whether the treatment with Ang-(1-7) during the prepuberty could attenuate the development of hypertension and cardiac injury in adult spontaneously hypertensive rats (SHRs). SHRs were treated with Ang-(1-7) (24 μg/kg/h) from age 4 to 7 weeks. Systolic blood pressure was measured by tail-cuff plethysmography up to 17th week. Thereafter, echocardiography was performed, and the rats were euthanized for the collection of tissues and blood. Ang-(1-7) did not change the systolic blood pressure but reduced the septal and posterior wall thickness, and cardiomyocyte hypertrophy and fibrosis in SHR. In addition, Ang-(1-7) reduced the gene expression of atrial natriuretic peptide and brain natriuretic peptide, increased the metalloproteinase 9 expression, and reduced the extracellular signal-regulated kinases 1/2 phosphorylation. Ang-(1-7) also prevented the reduction of Mas receptor but did not change the protein expression of angiotensin-converting enzyme, angiotensin-converting enzyme 2, AT1, and AT2. The treatment with Ang-(1-7) decreased the malondialdehyde (MDA) levels and increased superoxide dismutase-1 and catalase activities and protein expression of catalase. Our findings demonstrate that the treatment of SHR with Ang-(1-7) for 3 weeks early in life promotes beneficial effects in the heart later in life, even without altering blood pressure, through mechanisms involving the reduction of oxidative stress and ERK1/2 phosphorylation. In addition, this study supports the prepuberty as an important programming window.<br />Competing Interests: The authors declare no conflict of interest.<br /> (Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.)
- Subjects :
- Animals
Male
Fibrosis
Disease Models, Animal
Rats
Phosphorylation
Myocytes, Cardiac drug effects
Myocytes, Cardiac pathology
Myocytes, Cardiac metabolism
Natriuretic Peptide, Brain metabolism
Age Factors
Matrix Metalloproteinase 9 metabolism
Atrial Natriuretic Factor metabolism
Antihypertensive Agents pharmacology
Ventricular Remodeling drug effects
Angiotensin I pharmacology
Peptide Fragments pharmacology
Rats, Inbred SHR
Hypertension physiopathology
Hypertension drug therapy
Hypertension prevention & control
Cardiomegaly prevention & control
Cardiomegaly physiopathology
Cardiomegaly metabolism
Cardiomegaly drug therapy
Cardiomegaly pathology
Oxidative Stress drug effects
Blood Pressure drug effects
Subjects
Details
- Language :
- English
- ISSN :
- 1533-4023
- Volume :
- 83
- Issue :
- 5
- Database :
- MEDLINE
- Journal :
- Journal of cardiovascular pharmacology
- Publication Type :
- Academic Journal
- Accession number :
- 38498600
- Full Text :
- https://doi.org/10.1097/FJC.0000000000001530